Perrone Maria Grazia, Filieri Silvana, Azzariti Amalia, Armenise Domenico, Baldelli Olga Maria, Liturri Anselma, Sardanelli Anna Maria, Ferorelli Savina, Miciaccia Morena, Scilimati Antonio
Research Laboratory for Woman and Child Health, Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125 Bari, Italy.
Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, 70124 Bari, Italy.
Pharmaceuticals (Basel). 2025 Mar 5;18(3):371. doi: 10.3390/ph18030371.
: Identification of targetable biomarkers to improve early disease detection and overall patient outcomes is becoming an urgent need in clinical oncology. Ovarian cancer (OC) has one of the highest mortality rates among gynecological cancers. It is asymptomatic and almost always diagnosed at an advanced stage (III or IV), leading to a 5-year survival rate of approximately 35%. : Current therapeutic approaches for OC are very limited and mainly consist of cytoreductive surgery and cisplatin plus taxane-based chemotherapy. No gender and tumor specific biomarkers are known. Exosomes, lipid bilayer vesicles of endocytic origin secreted by most cell types, represent sources of information for their involvement in the onset and progression of many diseases. Hence, research on exosome contents as tools and targets in precise oncology therapy provides knowledge essential to improving diagnosis and prognosis of the disease. : This review attempts to give an overview of how exosomes are implicated in ovarian carcinoma pathogenesis to trigger further cancer exosome-based investigations aimed at developing ovarian cancer fine-tuning diagnostic methodologies. : It is essential to investigate exosome-based cancer drugs to advance understanding, improve treatment plans, create personalized strategies, ensure safety, and speed up clinical translation to increase patients' overall survival and quality of life. Papers published in PubMed and Web of Science databases in the last five years (2020-2024) were used as a bibliographic source.
识别可靶向的生物标志物以改善疾病早期检测和患者总体预后，已成为临床肿瘤学的迫切需求。卵巢癌（OC）是妇科癌症中死亡率最高的癌症之一。它没有症状，几乎总是在晚期（III期或IV期）被诊断出来，导致5年生存率约为35%。目前OC的治疗方法非常有限，主要包括减瘤手术和顺铂加紫杉烷类化疗。目前尚无性别和肿瘤特异性生物标志物。外泌体是大多数细胞类型分泌的内吞来源的脂质双层囊泡，因其参与多种疾病的发生和发展而成为信息来源。因此，对外泌体内容物作为精准肿瘤治疗工具和靶点的研究，为改善疾病诊断和预后提供了至关重要的知识。本综述试图概述外泌体如何参与卵巢癌发病机制，以引发更多基于癌症外泌体的研究，旨在开发卵巢癌微调诊断方法。研究基于外泌体的癌症药物对于增进理解、改进治疗方案、制定个性化策略、确保安全性以及加速临床转化以提高患者的总体生存率和生活质量至关重要。过去五年（2020 - 2024年）发表在PubMed和Web of Science数据库中的论文被用作文献来源。
